3.14 Clavulanic acid should not be included in the treatment of MDR/RR-TB patients on
longer
regimens.
(Strong recommendation against use, low certainty in the estimates of
effect)
3.15 In MDR/RR-TB patients on longer regimens, a total treatment duration of
18–20 months is suggested for most patients; the duration may be modified according
to the patient’s response to
therapy.
(Conditional recommendation, very low certainty in the estimates of
effect)
3.16 In MDR/RR-TB patients on longer regimens, a treatment duration of 15–17 months
after culture conversion is suggested for most patients; the duration may be modified
according to the patient’s response to
therapy.
(Conditional recommendation, very low certainty in the estimates of
effect)
3.17 In MDR/RR-TB patients on longer regimens containing amikacin or streptomycin,
an intensive phase of 6–7 months is suggested for most patients; the duration may be
modified according to the patient’s response to
therapy.
(Conditional recommendation, very low certainty in the estimates of
effect)
4. The bedaquiline, pretomanid and linezolid (BPaL)
regimen for multidrug-resistant tuberculosis with additional
fluoroquinolone resistance
4.1 A treatment regimen lasting 6–9 months, composed of bedaquiline, pretomanid
and linezolid (BPaL), may be used under operational research conditions in multidrug-
resistant tuberculosis (MDR-TB) patients with TB that is resistant to fluoroquinolones,
who have either had no previous exposure to bedaquiline and linezolid or have been
Do'stlaringiz bilan baham: |
